Keywords: pfizer, terminates, ph, iii, programs, fibromyalgia, gad
Pfizer terminates Ph III programs in fibromyalgia and GAD
Article | 02 March 2009
World drug giant Pfizer has terminated Phase III development programs for the investigational drugs esreboxetine for fibromyalgia and PD 332,334 for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
